Efficiency leap in drug research: Pharmaceutical companies reduce development times with AI
Reading Time: 3 minutes
Halved preclinical cycles: Leading companies like AstraZeneca, Sanofi, and Novartis are reducing the time for molecular design and early testing phases by up to 50 percent through AI models. Concrete pipeline advancements: Sanofi saved at least a year of development for the asthma candidate Lunsekimig, while Bristol Myers Squibb and Novartis identified new target structures and active substances. Tension with tech companies: Following the $1.5 trillion IPO, Anthropic is pushing into drug research with its own laboratories, but faces...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

